Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTBK1 | Q5TCY1 | 7/20 | 0.72 |
| ▸ | ROCK1 | Q13464 | 8/20 | 0.59 |
| ▸ | MAP3K14 | Q99558 | 3/20 | 0.59 |
| ▸ | PIKFYVE | Q9Y2I7 | 3/20 | 0.58 |
| ▸ | PAK4 | O96013 | 2/20 | 0.58 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1611765 | 0.91 | TTBK1 (0.60) | TTBK1ROCK1MAP3K14PIKFYVEPAK4 | |
| SCHEMBL1614510 | 0.89 | TTBK1 (0.58) | TTBK1ROCK1MAP3K14PIKFYVEPAK4 | |
| SCHEMBL1614244 | 0.89 | TTBK1 (0.58) | TTBK1ROCK1MAP3K14PIKFYVEPAK4 | |
| SCHEMBL1613536 | 0.88 | TTBK1 (0.56) | TTBK1ROCK1MAP3K14PIKFYVEPAK4 | |
| SCHEMBL1613400 | 0.88 | TTBK1 (0.56) | TTBK1ROCK1MAP3K14PIKFYVEPAK4 | |
| SCHEMBL1613085 | 0.87 | TTBK1 (0.56) | TTBK1ROCK1MAP3K14PIKFYVEPAK4 | |
| SCHEMBL1613287 | 0.87 | TTBK1 (0.56) | TTBK1ROCK1MAP3K14PIKFYVEPAK4 | |
| SCHEMBL1614201 | 0.87 | TTBK1 (0.56) | TTBK1ROCK1MAP3K14PIKFYVEPAK4 | |
| SCHEMBL1614503 | 0.86 | MAP3K14 (0.73) | TTBK1ROCK1MAP3K14PAK4MAP4K4 | |
| SCHEMBL1614052 | 0.86 | MAP3K14 (0.73) | TTBK1ROCK1MAP3K14PAK4MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2315751-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | Amgen Inc. (US) | 2011-05-04 | — | — | EP | disclosed |
| US-20110086834-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | AMGEN INC. (US) | 2011-04-14 | — | — | US | disclosed |
| US-20110086834-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | AMGEN INC. (US) | 2011-04-14 | — | — | US | disclosed |
| WO-2009158011-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | AMGEN INC. (US) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086834-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | NFKBIA, MAP3K1, MAP3K2 | TTBK1 888/4885ROCK1 609/4885MAP3K14 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.